Global Acute Dystonia Market, By Drug Class, By Age Group, By Distribution Channel, By Geography .

Description

The global acute dystonia market was valued US$ 120.7 Mn in 2023 and is expected to reach US$ 155.0 Mn by 2031 growing at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 120.7 Mn
Historical Data for:	2019 to 2023	Forecast Period:	2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	3.20%	2030/2031 Value Projection:	US$ 155.0 Mn

Figure 1. Global Acute Dystonia Market Share (%), By Region, 2024

Acute dystonia is a movement disorder characterized by involuntary muscle contractions that lead to repetitive movements or abnormal postures. These contractions can be painful and are often caused by a sudden onset of muscle spasms. Acute dystonia can affect any part of the body, including the neck (cervical dystonia), eyes (oculogyric crisis), jaw or tongue, and the limbs. The condition can have varying causes, including:

Drug-induced Dystonia: One of the most common causes. It can occur as a side effect of certain medications, particularly antipsychotic drugs that affect dopamine pathways in the brain.
Idiopathic Dystonia: Where the cause is unknown
Secondary Dystonia: Resulting from an underlying medical condition such as Wilson's disease, Huntington's disease, Parkinson's disease, brain injury, or stroke

Market Dynamics:

The global acute dystonia market is driven by the rising prevalence of neurological disorders that can induce acute dystonia like Parkinson's disease, cerebral palsy, and tardive dyskinesia. For instance, on August 9, 2023, according to a report published by the World Health Organization (WHO), Parkinson's disease (PD) is a brain condition that causes problems with movement, mental health, sleep, pain, and other health issues. Nearly one million people in the U.S. were living with Parkinson's disease (PD) in 2021, while this number is expected to rise to 1.2 million by 2030. Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's disease.

Furthermore, in March 2022, according to a report published by the National Center for Biotechnology Information, cerebral palsy occurs in 2.3 to 3.6 out of every 1,000 children in the U.S., every year. While spastic cerebral palsy is the most common, making up 61 percent to 76.9 percent of all cerebral palsy cases.

Key Features of the Study:

This report provides an in-depth analysis of the global acute dystonia market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global acute dystonia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Fresenius Kabi, Amar Healthcare, Johnson & Johnson ,PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc. , Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global acute dystonia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute dystonia market

Detailed Segmentation:

Global Acute Dystonia Market, By Drug Class
- Anticholinergic Agents
- Benzodiazepines
- Others (Neurotoxin, etc.)
Global Acute Dystonia Market, By Age Group
- Children
- Adult
Global Acute Dystonia Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Acute Dystonia Market, By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Top Companies in the Global Acute Dystonia Market:
- Fresenius Kabi
- Amar Healthcare
- Johnson & Johnson
- PAI Pharma
- Pfizer Inc.
- Souvin Pharmaceuticals Pvt.Ltd
- Bayer Healthcare
- S.Pharmachem
- Remedy Labs
- Wan Bury
- F.Hoffmann-La Roche Ltd
- Bausch Health Companies, Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd
- Torrent Pharmaceuticals Ltd.
- Mallinckrodt Pharmaceuticals
- Amneal Pharmaceuticals LLC
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.

Product Code: CMI6661

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Age Group
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing prevalence of dystonia
- Side effects associated with drugs
- Understanding changing treatment patterns
Key Highlights
Regulatory Guidelines
Market Trends
PEST Analysis
Investments and Funding
Mergers, Acquisitions, and Collaborations
Product Mapping
Identification of Top Market Players
Adoption of Various Business Development Strategies by the Market players
Healthcare Spending by Country

4. Global Acute Dystonia Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Acute Dystonia Market, By Drug Class, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Anticholinergic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Benzodiazepines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Others (Neurotoxin, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

6. Global Acute Dystonia Market, By Age Group, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Children
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Acute Dystonia Market, By Distribution Channel, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Acute Dystonia Market, By Region, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020 - 2031
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profile
- Fresenius Kabi
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Amar Healthcare
- Johnson & Johnson
- PAI Pharma
- Pfizer Inc.
- Souvin Pharmaceuticals Pvt.Ltd
- Bayer Healthcare
- S.Pharmachem
- Remedy Labs
- Wan Bury
- Hoffmann-La Roche Ltd
- Bausch Health Companies, Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd
- Torrent Pharmaceuticals Ltd.
- Mallinckrodt Pharmaceuticals
- Amneal Pharmaceuticals LLC
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
Analyst Views

10. Section

References
Research Methodology
About us